Probing cortical sites of antipsychotic drug action with in vivo receptor imaging

Behavioural Neurology

Volumn 12, Issue 1-2, 2000, Pages 3-9

  Shaw, P ^a   Pilowsky, L S ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BROMINE; CARBON 11; CHLORPROMAZINE; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; EPIDEPRIDE; HALOPERIDOL; IODINE 123; IOMAZENIL; ISOREMOXIPRIDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; SEROTONIN RECEPTOR; SERTINDOLE;

BRAIN; HUMAN; IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0033834653     PISSN: 09534180     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/184707     Document Type: Review

References (56)

1. Do novel antipsychotics have similar pharmacological characteristics?
2. D1 receptor antagonists in schizophrenia
3. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenia
4. Upregulation of GABA receptor binding on neurones of the prefrontal cortex in schizophrenia
5. 123l-epidepride study
6. Preliminary results: D2/D2-like receptor binding in temporal cortex and striatum in sertindole and olanzapine treated patients
7. 5HT(2a) receptor blockade in vivo in schizophrenic patients treated with atypical antipsychotics: SPET findings
8. Correlation between reduced in vivo benzodiazepine receptor binding and severity of symptoms in schizophrenia
9. The current status of the dopamine hypothesis of schizophrenia
10. Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs
11. D1 and D2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
12. 2 receptor binding in risperidone-treated schizophrenic patients
13. PET quantification of extrastriatal D2 and D3 dopamine receptors
14. 2 receptor occupancy in healthy volunteers treated with ziprasidone
15. Extrastriatal and striatal dopamine receptor occupancy by haloperidol and clozapine measured with PET
16. Extrastriatal dopamine D2 receptors: Distribution, pharmacological characterisation and region-specific regulation
17. Mechanism of the antipsychotic effects in the treatment of acute schizophrenia
18. Towards more effective antipsychotic treatment
19. High levels of D2 occupancy with low dose haloperidol treatment
20. Does dopamine D2 occupancy predict antipsychotic response and side effects. A double blind test of the hypothesis
21. Visualisation of extrastriatal D2 dopamine receptors in the human brain
22. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipfide
23. Schizophrenia with good and poor outcome, 1: Early Clinical Features, response to neuroleptics and signs of organic dysfunction
24. Differential regulation of D4 and D2 dopamine receptor mRNA in cerebral cortex and neostriatum
25. The cerebral cortex: A case for a common site of action of antipsychotics
26. IBZM SPECT imaging of striatal D2 receptors in psychotic patients treated with a novel antipsychotic quetiapine in comparison to clozapine and haloperidol
27. Study of a new schizophrenic drug sernyl
28. The pharmacology of CNS 1261: An NMDA ion channel blocker
29. An overview of the mechanism of action Of clozapine
30. Imaging of NMDA receptor activation in acute stroke
31. Central D2 dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients
32. 2 receptor occupancy in relation to clozapine serum concentration - A PET study in schizophrenic patients
33. PET finding of a high striatal D2 receptor occupancy in olanzapine treated patients
34. 2 and D2 dopamine receptor occupancy in the living human brain: A PET study with risperidone
35. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
36. 2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects
37. 125I-L 750, 667 a novel radioligand for dopamine D4 receptors
38. Relation Of Neuroleptic Drug Effects At Dopamine, Serotonin, Adrenergic And Histaminergic Receptors To Clinical Potency
39. Individual variation in D2 dopamine receptor occupancy in clozapine treated patients
40. Clozapine, SPET and the D2 dopamine receptor blockade hypothesis of schizophrenia
41. 123I IBZM SPET study
42. Dopamine D2 receptor occupancy of in vivo by a novel atypical olanzapinean 123 I-IBZM SPET study
43. Limbic selectivity of clozapine
44. Amisulpiride: From animal pharmacology to therapeutic action
45. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
46. Phencyclidine acts at sigma sites to induce c-los gene expression
47. Association between clozapine response and allelic variation in the 5-HT(2C) receptor gene
48. Striatal and extra-striatal D2/D3 receptor blockade for the atypical antipsychotic quetiapine
49. GABA blockade, dopamine in schizophrenia
50. Biochemical and neurochemical data suggest functional differences between dopamine D2 and D3 receptors
51. 5HT2a receptor blockade in schizophrenic patients treated with risperidone or clozapine: A 1231-5-1-R-91150 SPET study
52. Binding of antipsychotic drugs to cortical 5HT(2a) receptors: A PET study of chlorpromazine, clozapine and amisupliride in schizophrenic patients
53. Dopamine blockade and clinical response - Evidence for 2 biological subgroups in schizophrenia
54. Actions of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat
55. In vivo interaction of antipsychotic drugs with extrastriatal D2 dopamine receptors